Kraig Biocraft Laboratories Prepares to Accelerate Production Launch following Spring Trials Success
Kraig Biocraft Laboratories (OTCQB: KBLB) has completed its spring spider silk production trials and is set to expand production in 2024. The company identified five key input parameters—nutrition, climate, genetic, staffing, and rearing conditions—that improved silkworm genetics and production processes, resulting in the largest and strongest silkworms and cocoons to date. Under the guidance of Dr. Nirmal Kumar, the team achieved significant advancements and is now accelerating the launch of larger-scale operations, starting nearly a month ahead of schedule with the next generation of BAM-1 spider silk hybrids.
- Successful spring trials identified key input parameters enhancing production.
- Significant advancements in silkworm genetics, feeding cycles, and facility layout.
- Largest and strongest silkworms and cocoons produced to date.
- Accelerated launch of larger-scale operations nearly a month ahead of schedule.
- Projected growth trajectory targeting metric ton levels of spider silk production in 2024.
- Details of operational advancements remain trade secrets, limiting transparency.
- Potential risks associated with the rapid expansion and scaling of operations.
- Dependency on key input parameters may pose challenges if conditions change.
Ann Arbor, Michigan--(Newsfile Corp. - May 20, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has completed its analysis of its spring spider silk production trials. Kraig Labs is rapidly integrating lessons learned from the production trials to establish a strong foundation for production expansion in 2024.
The Company identified key input parameters in five specific aspects of its production operations that contributed to the exceptional results in the spring trials. Through the identification and close monitoring of these inputs, Kraig Labs expects that it will be able to sustain its projected growth trajectory, targeting metric ton levels of spider silk production in 2024.
These process enhancements range from major advancements in our silkworm genetics introduced in Q1, to minor modifications in feeding cycles, feedstock selection, and facility layout. When combined, these process improvements resulted in the largest, strongest, and most robust silkworms and recombinant spider silk cocoons that Kraig Labs has ever produced.
While the details of these operational advancements will remain the Company's trade secrets, these enhancements broadly fall into five unique categories: nutrition, climate, genetic, staffing, and rearing conditions. Kraig Labs made significant advancements in each of these areas during the spring trials under the guidance of celebrated sericulture expert, Dr. Nirmal Kumar.
"The amazing successes of the spring production trials demonstrate that we have unlocked the key to metric ton level spider silk production," said Founder and CEO, Kim Thompson. "Our team is ready. Our silkworm genetics are ready. Now is the time to build out the production capacity and scale our operations to meet the demand for spider silk."
With these operational improvements in place, the Company has elected to accelerate its launch of larger-scale operations and accelerate its production schedule. The next generation of BAM-1 spider silk hybrids are now prepared for launch nearly a full month ahead of schedule. Kraig Labs will continue to keep its shareholders updated as the BAM-1 hybrid production expansion continues and the Company brings additional production capacity online.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209827
FAQ
What recent advancements did Kraig Biocraft Laboratories report?
When did Kraig Biocraft Laboratories complete its spring spider silk production trials?
What are the key input parameters identified by Kraig Biocraft Laboratories?
What is Kraig Biocraft Laboratories' stock symbol?
How is Kraig Biocraft Laboratories accelerating its production schedule?
Who guided the recent advancements at Kraig Biocraft Laboratories?
What production levels is Kraig Biocraft Laboratories targeting for 2024?
